References

American Society of Clinical Oncology: policy for relationships with companies

10.1200/jco.2016.71.8510 · 2017 · External reference

The effect of financial conflict of interest, disclosure status, and relevance on medical research from the United States

10.1007/s11606-018-4784-0 · 2019 · External reference

The effects of public disclosure of industry payments to physicians on patient trust: a randomized experiment

10.1007/s11606-017-4122-y · 2017 · External reference

Are financial payments from the pharmaceutical industry associated with physician prescribing?: A systematic review

10.7326/m20-5665 · 2021 · External reference

Association between industry payments and prescribing costly medications: an observational study using open payments and Medicare part D data

10.1186/s12913-018-3043-8 · 2018 · External reference

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

10.1001/jama.289.4.454 · 2003 · External reference

Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study

10.1136/bmj.i6770 · 2017 · External reference

Industry sponsorship bias in cost effectiveness analysis: registry based analysis

10.1136/bmj-2021-069573 · 2022 · External reference

Cost-effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal

10.1200/jco.2017.76.5941 · 2018 · External reference

Industry funding of patient and health consumer organisations: systematic review with meta-analysis

10.1136/bmj.l6925 · 2020 · External reference

Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices

10.2105/ajph.2010.300027 · 2011 · External reference

Provenance and funding of extremely cited biomedical articles published between 2003 and 2024

10.1001/jamahealthforum.2025.3045 · 2025 · External reference

Practice-level clustering of industry payments to clinicians

10.1111/1475-6773.70004 · 2025 · External reference

Spending on phased clinical development of approved drugs by the US National Institutes of Health compared with industry

10.1001/jamahealthforum.2023.1921 · 2023 · External reference

Does targeted, disease-specific public research funding influence pharmaceutical innovation?

10.1002/pam.21640 · 2012 · External reference

Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies

10.1093/jncics/pkaa034 · 2020 · External reference

Patient enrollment to industry-sponsored versus federally-sponsored cancer clinical trials

10.1200/jco.24.00843 · 2024 · External reference

What features should an effective system for declaring and managing conflicts of interest in healthcare have? An adapted Delphi study of key stakeholders in the UK

10.1136/bmjopen-2025-103058 · 2025 · External reference

Physician perspectives on pharmaceutical promotion

10.1001/jamahealthforum.2025.3521 · 2025 · External reference

Research gets funding boost for FY 2023

10.1158/2159-8290.cd-nb2023-0004 · 2023 · External reference

Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries

10.1001/jamahealthforum.2022.1229 · 2022 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Conflicts of interest for patient-advocacy organizations

10.1056/nejmsr1610625 · 2017 · External reference

Financial conflicts of interest among oncologist authors of reports of clinical drug trials

10.1001/jamaoncol.2018.3738 · 2018 · External reference

Financial relationships with industry among National Comprehensive Cancer Network guideline authors

10.1001/jamaoncol.2016.2710 · 2016 · External reference

Oncologic Drugs Advisory Committee recommendations and approval of cancer drugs by the US Food and Drug Administration

10.1001/jamaoncol.2015.6479 · 2016 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

Conducting systematic reviews of association (etiology): the Joanna Briggs Institute’s approach

10.1097/xeb.0000000000000064 · 2015 · External reference

Introduction to the GRADE tool for rating certainty in evidence and recommendations

10.1016/j.cegh.2023.101484 · 2024 · External reference

Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops

10.1111/eci.14184 · 2024 · External reference

Evolution of the randomized clinical trial in the era of precision oncology

10.1001/jamaoncol.2021.0379 · 2021 · External reference

Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing

10.1371/journal.pone.0209383 · 2018 · External reference

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study

10.1136/bmj-2023-075512 · 2023 · External reference

US nationwide disclosure of industry payments and public trust in physicians

10.1001/jamanetworkopen.2019.1947 · 2019 · External reference

The impact of disclosing financial ties in research and clinical care: a systematic review

10.1001/archinternmed.2010.39 · 2010 · External reference

The influence of industry sponsorship on the research agenda: a scoping review

10.2105/ajph.2018.304677 · 2018 · External reference

The studies industry neglects: characteristics of cancer clinical trials conducted by federal versus industry sponsors

10.1200/jco.2025.43.16_suppl.11095 · 2025 · External reference

A disclosure form for work submitted to medical journals - a proposal from the International Committee of Medical Journal Editors

10.1056/nejme2000647 · 2020 · External reference

Disclosing conflict of interest does not mitigate healthcare bias and harm: it is time to sever industry ties

10.1111/eci.13344 · 2020 · External reference

Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts

10.1001/jamainternmed.2016.1709 · 2016 · External reference

Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing

10.1001/jamainternmed.2018.1999 · 2018 · External reference

Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries

10.1001/jamainternmed.2016.2765 · 2016 · External reference

Trends in industry payments to medical oncologists in the United States since the inception of the Open Payments program, 2014 to 2019

10.1001/jamaoncol.2020.6591 · 2021 · External reference

Industry payments to pediatricians in the United States between 2013 and 2021

10.1177/00099228231218850 · 2024 · External reference

Industry relationships with pediatricians: findings from the Open Payments Sunshine Act

10.1542/peds.2015-4440 · 2016 · External reference

Correlation between National Institutes of Health funding for pediatric research and pediatric disease burden in the US

10.1001/jamapediatrics.2021.3360 · 2021 · External reference

Characteristics of biomedical industry payments to teaching hospitals

10.1377/hlthaff.2020.00385 · 2020 · External reference

Institutional academic industry relationships

10.1001/jama.298.15.1779 · 2007 · External reference

Evaluation of industry payments to US advanced practice clinicians in 2021

10.1001/jamanetworkopen.2022.42869 · 2022 · External reference

Disrupted federal funding for extramural cancer research

10.1001/jamaoncol.2025.4985 · 2026 · External reference

Potential trade-offs of proposed cuts to the US National Institutes of Health

10.1001/jamahealthforum.2025.2228 · 2025 · External reference

Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship

10.1002/pbc.30925 · 2024 · External reference

Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study

10.1016/j.ejca.2023.05.008 · 2023 · External reference

Intercontinental collaboration in clinical trials for children and adolescents with cancerA systematic review by ACCELERATE

10.1002/cam4.4356 · 2021 · External reference

The clinical trial transparency in oncology significantly increased over the recent years

10.1016/j.jclinepi.2019.11.018 · 2020 · External reference

Intersectionality between country, gender and funding in authorship for phase III trials presented at the ASCO Annual Meeting 2022

10.1200/go.24.00238 · 2024 · External reference

Association between health-related quality-of-life results, outcomes of efficacy and drug approvals: a meta-research study of randomized phase III trials in oncology

10.1016/j.esmoop.2024.103654 · 2024 · External reference

Effect of sponsor on enrollment criteria in non-small cell lung cancer clinical trials

10.1016/j.jcpo.2022.100336 · 2022 · External reference

Industry funding of oncology randomised controlled trials: implications for design, results and interpretation

10.1016/j.clon.2021.08.003 · 2022 · External reference

Is clinical research serving the needs of the global cancer burden? An analysis of contemporary global radiation therapy randomized controlled trials

10.1016/j.ijrobp.2022.01.053 · 2022 · External reference

Secondary endpoint utilization and publication rate among phase III oncology trials

10.1158/2767-9764.crc-24-0265 · 2024 · External reference

Clinical outcomes of first-line therapies for advanced non-small cell lung cancer: a systematic review of trials published between 2010 and 2020

10.1097/coc.0000000000001031 · 2023 · External reference

Impact of global enrollment on race, ethnicity, and age representation in pivotal gynecologic cancer trials leading to US Food and Drug Administration drug approvals

10.1200/go-24-00636 · 2025 · External reference

Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: who decided that MRD can be a novel regulatory endpoint in myeloma?

10.1016/j.jcpo.2024.100529 · 2025 · External reference

Financial conflict of interest and academic influence among experts speaking on behalf of the pharmaceutical industry at the US Food and Drug Administration’s Oncologic Drugs Advisory Committee meetings

10.1016/j.mayocp.2017.04.014 · 2017 · External reference

Financial relationships with industry of editorial board members of the three journals of the American Society for Radiation Oncology

10.1016/j.ijrobp.2017.03.020 · 2017 · External reference

Financial ties between leaders of influential US professional medical associations and industry: cross sectional study

10.1136/bmj.m1505 · 2020 · External reference

Nonresearch pharmaceutical industry payments to oncology physician editors

10.1634/theoncologist.2019-0828 · 2020 · External reference

Payments by drug and medical device manufacturers to Society of Urologic Oncology fellowship program directors

10.1097/upj.0000000000000814 · 2025 · External reference

Industry funding of cancer patient advocacy organizations

10.1016/j.mayocp.2016.08.015 · 2016 · External reference

Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019

10.1002/cncr.32997 · 2020 · External reference

Assessing neoadjuvant therapy recommendations in 19 national and international guidelines for rectal cancer

10.1007/s10151-024-02969-5 · 2024 · External reference

Prevalence of financial conflicts of interest among authors of clinical guidelines related to high-revenue medications

10.1001/jamainternmed.2018.5106 · 2018 · External reference

Evidence underlying recommendations and payments from industry to authors of the National Comprehensive Cancer Network guidelines

10.1634/theoncologist.2017-0655 · 2019 · External reference

Financial conflicts of interest among oncology clinical pathway vendors

10.1001/jamaoncol.2017.4473 · 2018 · External reference

Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines

10.1002/cncr.32408 · 2019 · External reference

Promotional payments to medical oncologists and urologists and prescriptions for abiraterone and enzalutamide

10.1016/j.urology.2021.10.042 · 2022 · External reference

Increasing financial payments from industry to medical oncologists in the United States, 2014-2017

10.6004/jnccn.2021.7024 · 2021 · External reference

Comparison of industry payments in 2017 with annual salary in a cohort of academic oncologists

10.1001/jamainternmed.2020.0090 · 2020 · External reference

Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021

10.1080/10428194.2024.2317344 · 2024 · External reference

Trends in financial relationships between industry and radiation oncologists versus other physicians in the United States from 2014 to 2018

10.1016/j.ijrobp.2020.08.043 · 2021 · External reference

Disparities in industry funding among colorectal surgeons: a cross-sectional study

10.1007/s00464-022-09062-8 · 2022 · External reference

Association of financial conflicts of interest with academic productivity among junior faculty in hematology and oncology

2022 · External reference

Exploring the link between factors in musculoskeletal oncology surgery fellowships and industry supplemental income

10.7759/cureus.70714 · 2024 · External reference